Clinical Trial Update: Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pegylated liposomal doxorubicin plus anlotinib as neoadjuvant therapy for stage III soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Anlotinib (anlotinib)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Yong Chen | Conditions: Stage III Adult Soft Tissue Sarcoma | Phase 2 | Status: UNKNOWN